Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | ACR | P10323 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19341482 | 0.92 | PTGS2 (0.38) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL19341481 | 0.91 | PTGS2 (0.39) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL15929180 | 0.88 | PTGS2 (0.36) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL15929129 | 0.85 | AKR1C3 (0.45) | PTGS2AKR1C3AKR1C2LMNAMAPT | |
| SCHEMBL15929092 | 0.85 | HDAC3 (0.44) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL19341473 | 0.83 | PTGS2 (0.34) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL15929115 | 0.81 | MAPT (0.40) | LMNAMAPTKMT2A | |
| SCHEMBL19341478 | 0.77 | AKR1C3 (0.46) | PTGS2AKR1C3AKR1C2PTGS1LMNA | |
| SCHEMBL15929189 | 0.75 | PTGS2 (0.48) | PTGS2PTGS1MAPTKMT2A | |
| SCHEMBL19341483 | 0.75 | AKR1C3 (0.48) | PTGS2AKR1C3AKR1C2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2017-09-14 | — | — | US | disclosed |
| US-9688607-B2 | No- and H2S-releasing compounds | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2017-06-27 | — | — | US | disclosed |
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | PTGS1, NOS2, NOS1 | PTGS2 4/4885AKR1C3 2456/4885AKR1C2 2270/4885 |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | NOS2, NOS3, NOS1 | PTGS2 9/4885AKR1C3 2812/4885AKR1C2 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.